EPCAM and cancer: Given the expression of CD47 and PD-L1 during tumorigenesis, designed EpCAM-targeted cationic liposomes containing si-CD47 and si-PD-L1 could target EpCAM-rich cancer cells to downregulate both CD47 and PD-L1 proteins.